title: Leishmania resistance to miltefosine associated with genetic marker.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Cojean
authors.forename: Sandrine
authors.initials: S
authors.lastname: Houzé
authors.forename: Djamel
authors.initials: D
authors.lastname: Haouchine
authors.forename: Françoise
authors.initials: F
authors.lastname: Huteau
authors.forename: Sylvie
authors.initials: S
authors.lastname: Lariven
authors.forename: Véronique
authors.initials: V
authors.lastname: Hubert
authors.forename: Florence
authors.initials: F
authors.lastname: Michard
authors.forename: Christian
authors.initials: C
authors.lastname: Bories
authors.forename: Francine
authors.initials: F
authors.lastname: Pratlong
authors.forename: Jacques
authors.initials: J
authors.lastname: Le Bras
authors.forename: Philippe Marie
authors.initials: PM
authors.lastname: Loiseau
authors.forename: Sophie
authors.initials: S
authors.lastname: Matheron
mesh_terms: D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006801:Humans; D020128:Inhibitory Concentration 50; D007893:Leishmania donovani / Q000187:drug effects*; D007898:Leishmaniasis, Visceral / Q000175:diagnosis* / Q000469:parasitology / Q000517:prevention & control*; D060046:Maintenance Chemotherapy; D008875:Middle Aged; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine; D000666:Amphotericin B